Objective: The authors evaluated the accuracy of in-house boosted-p24 antigen assay for diagnosis of perinatal HIV infection.
Material And Method: The author has retrospectively reviewed the medical records of infants born to HIV-positive mothers. The infants were tested for boosted-p24 antigen assay at the age of 1-2 months and 4-6 months. HIV infection was defined as positive anti-HIV at the age 18 months or older, or had positive HIV-PCR with clinical signs and symptoms compatible with HIV/AIDS.
Results: There were 168 infants included in this review and six were HIV-infected. The boosted-p24 antigen assay had the sensitivity, specificity, positive predictive value, and negative predictive value of 33.33%, 98.27%, 50%, and 95.8%, respectively at 1-2 month-old, and 100%, 98.27%, 71.43%, and 100%, respectively at 4-6 month-old.
Conclusion: Boosted-p24 antigen assay could be a cheaper alternative test to help diagnosis of perinatal HIV infection in infants. The test was very accurate when performed at 4-6 months.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Can lesion volume and prostate-specific antigen density play a role in detecting clinically significant prostate cancer in Prostate Imaging Reporting and Data System-3 lesions on multiparametric magnetic resonance imaging?
Indian J Urol
January 2025
Uro-Oncology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.
Introduction: Recently, the Prostate Imaging Reporting and Data System - 3 lesions (PI-RADS 3) have been sub classified into "3a" - lesions with a volume of <0.5 mL and "3b" - lesions exceeding 0.5 mL, whereas the prostate-specific antigen density (PSAD) is an established adjunct tool for predicting clinically significant prostate cancer (csPCa).
View Article and Find Full Text PDFScreening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps.
BMJ Oncol
April 2023
Department of Urology, Cancer Institute, Erasmus University Rotterdam, Rotterdam, Zuid-Holland, Netherlands.
Long-term screening with serum prostate-specific antigen (PSA) and systematic prostate biopsies can reduce prostate cancer mortality but leads to unacceptable overdiagnosis. Over the past decade, diagnostic methods have improved and the indolent nature of low-grade prostate cancer has been established. These advances now enable more selective detection of potentially lethal prostate cancer.
View Article and Find Full Text PDFPrevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study.
BMJ Oncol
August 2023
Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Objective: In men with a raised prostate-specific antigen (PSA), MRI increases the detection of clinically significant cancer and reduces overdiagnosis, with fewer biopsies. MRI as a screening tool has not been assessed independently of PSA in a formal screening study. We report a systematic community-based assessment of the prevalence of prostate MRI lesions in an age-selected population.
View Article and Find Full Text PDFTale of two zones: investigating the clinical outcomes and research gaps in peripheral and transition zone prostate cancer through a systematic review and meta-analysis.
BMJ Oncol
April 2024
Translational Oncogenomics, Cancer Research UK Manchester Centre, The University of Manchester, Manchester, UK.
Objective: To assess pathological characteristics, clinical features and outcomes of patients diagnosed with peripheral zone (PZ) and transition zone (TZ) prostate cancer after prostatectomy.
Methods And Analysis: We systematically reviewed PubMed, EMBASE and MEDLINE. Primary endpoints were biochemical relapse-free survival (bRFS) and distant metastases rate; secondary endpoints included clinical and pathological features.
Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review.
BMJ Oncol
February 2024
Division of Cancer Sciences, The University of Manchester, Manchester, UK.
Objective: To review the efficacy and safety of low-dose versus standard-dose enzalutamide, apalutamide or darolutamide treatment for metastatic prostate cancer.
Methods And Analysis: Keyword searches in MEDLINE and EMBASE up to 1 June 2023, with forward and backward citation searches of potentially relevant studies. Studies were included if primary outcome data were reported for patients with metastatic prostate cancer who had received reduced doses of enzalutamide, apalutamide or darolutamide.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!